July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic (PELE) clinical trial, which will evaluate the safety and effectiveness of the Onyx Liquid Embolic System (LES) for embolization of arterial hemorrhage in the peripheral vasculature. The first procedure was performed by Dr. Christopher Stark at Albany Medical Center.

July 22, 2025 — HeartBeam, Inc., a medical technology company focused on transforming cardiac care by providing powerful personalized insights, recently announced it has been awarded the Innovation Award in Remote Cardiac Diagnostics as part of the 2025 Medical Device Network Excellence Awards. The award honors HeartBeam’s  FDA-cleared electrocardiogram (ECG) technology that enables clinical-grade diagnostics for arrhythmia assessment outside of traditional healthcare settings, expanding access to timely and actionable cardiac care.

July 21, 2025. — Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to implant an FDA-approved novel leadless system that provides cardiac resynchronization therapy to patients with heart failure. Cardiac resynchronization therapy improves the timing of the heart's contractions, helping to restore the normal rhythm of the heartbeat. The first procedure was recently performed by Robert Canby, M.D., cardiac electrophysiologist at TCAI.

July 17, 2025— Heartflow, Inc. recently announced new data for its AI-enabled Heartflow Plaque Analysis, including final primary endpoint data from the DECIDE Registry. Data from the DECIDE Registry showed Heartflow Plaque Analysis led to medical management change in over half of patients beyond coronary computed tomography angiography (CCTA) alone, regardless of traditional risk factors or CCTA findings.

July 17, 2025 — Royal Philips, a global leader in health technology, has launched the Philips ECG AI Marketplace, a platform that gives cardiac care teams access to multiple vendor offerings all in one central location to help clinicians manage and implement AI-powered diagnostic tools more easily. Anumana, an AI-driven health technology company committed to transforming the continuum of cardiac care, is the first organization to leverage Philips’ platform.

July 15, 2025 – Cleerly has announced that EviCore, a leading radiology benefit manager providing coverage guidelines to commercial health insurers, has released updated guidelines with positive coverage recommendations for AI-guided quantitative coronary CT angiography (AI-QCT), including Cleerly LABS Plaque Analysis. The updated coverage guidelines become effective Oct, 1, 2025.

EviCore's recommended patient selection criteria align with those established in the Medicare Local Coverage Determinations (LCDs) and include:

July 16, 2025 — The American Heart Association has appointed two leading health and science leaders, Jennifer Ashton, M.D., M.S. and Joseph Woo, M.D., FAHA, to its volunteer Board of Directors, effective July 1, 2025.

Ashton and Woo bring clinical leadership, health media influence and scientific innovation to the Association as it enters its second century, intensifying its efforts to change the future of health and improve cardiovascular and cerebrovascular health outcomes.

July 11, 2025 — Heartflow, Inc. has announced that its Heartflow Plaque Analysis will be included in updated cardiac imaging guidelines by radiology benefit manager EviCore, which provides coverage guidelines to leading commercial health insurers.

July 9, 2025 — Cleerly, a leader in advanced cardiovascular imaging, will be presenting new research at the Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting 2025. The conference will take place July 17-20, 2025, at the Palais des Congrès de Montréal in Montreal, Canada. This annual event brings together leading cardiovascular imaging specialists, researchers, and technology innovators from around the world to share the latest advances in cardiovascular computed tomography.

July 10, 2025 — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, will be featured along with its PlaqueIQ image analysis software at the 20th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT 2025), taking place July 17-20 at Palais des Congrès de Montréal.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now